Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Trish Specter

Physician Assistant Saint Louis, MO Physician Assistant

NPI 1538552120 CMS profile 10853880

520 S Elm Ave, Saint Louis, MO 63119

Open in the dashboard

General payments

$8,417

479 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Trish Specter of Saint Louis, MO is reported in the CMS Open Payments database as having received $8,417 across 479 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,827 93
2024 General $1,715 81
2023 General $1,627 93
2022 General $1,839 103
2021 General $1,410 109

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Trish Specter
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Trish Specter were reported at $1,827. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Trish Specter Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,410 $132 $37–$438 $132
2022 $1,839 $155 $48–$522 $149
2023 $1,627 $167 $52–$557 $160
2024 $1,715 $178 $55–$600 $164
2025 $1,827 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,600 143 payments
  2. Janssen Biotech, Inc. $1,191 75 payments
  3. Pfizer Inc. $1,116 74 payments
  4. Novartis Pharmaceuticals Corporation $645 42 payments
  5. Amgen Inc. $565 35 payments
  6. UCB, Inc. $401 20 payments
  7. GlaxoSmithKline, LLC. $337 21 payments
  8. Lilly USA, LLC $255 14 payments
  9. Janssen Scientific Affairs, LLC $245 2 payments
  10. Organon LLC $150 7 payments
  11. Other $914 46 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,370 476 payments
  2. Education $47 3 payments
Products named General payments · program years 2021–2025
  1. RINVOQ $1,933 105 payments
  2. TREMFYA $1,193 56 payments
  3. XELJANZ $1,046 69 payments
  4. SIMPONI ARIA $569 43 payments
  5. SKYRIZI $425 25 payments
  6. COSENTYX $391 25 payments
  7. BENLYSTA $337 21 payments
  8. REMICADE $288 23 payments
  9. TALTZ $255 14 payments
  10. TAVNEOS $221 12 payments
  11. Other $3,280 198 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

1,579

Median for Physician Assistant: 241

Drug cost

$933,617

Median for Physician Assistant: $4,110

Branded share of claims

34.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 42 $483,205
Rinvoq Upadacitinib Brand 32 $200,657
Enbrel Sureclick Etanercept Brand 20 $153,072
Actemra Actpen Tocilizumab Brand 11 $30,033
Teriparatide Generic 11 $26,426
Methotrexate Methotrexate Sodium Brand 421 $10,781
Hydroxychloroquine Sulfate Generic 217 $7,855
Leflunomide Generic 128 $6,514
Celecoxib Generic 67 $3,956
Mycophenolate Mofetil Generic 18 $3,377

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
$477 32 —
TREMFYA
$233 — —
SKYRIZI
$219 — —
Cimzia
$119 — —
XELJANZ
$97 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

479 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record